Evidence map›Paper›PMID 27481548›Full record

ArticleHepatology (Baltimore, Md.)2016

Liver transplantation for "very early" intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment.

G Sapisochin, M Facciuto, L Rubbia-Brandt, J Marti, N Mehta, F Y Yao, E Vibert, D Cherqui, D R Grant, R Hernandez-Alejandro and 27 more

2 registry-linked trialsOpen access · greenAbstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Hepatology (Baltimore, Md.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 158 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
158citing papers in PubMed, 2 pooled it
23.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02878473 phase2terminatednot on this mapstarted 2018, after this paper: background citation

Liver Transplantation for the Treatment of Early Stages of Intrahepatic Cholangiocarcinoma in Cirrhotics

TypeinterventionalSponsorUniversity Health Network, TorontoRan2018 to 2024Enrolled2ConditionsIntrahepatic CholangiocarcinomaArmsDeceased donor Liver Transplantation
NCT06140134 recruitingnot on this mapstarted 2023, after this paper: background citation

A Single-Arm Nonrandomized Phase II Study of Liver Transplantation in Locally Advanced Unresectable Non-Metastatic Intrahepatic Cholangiocarcinoma Treated With Neoadjuvant Systemic Therapy

Typeobservational_patient_registrySponsorRutgers, The State University of New JerseyRan2023 to 2029Enrolled30ConditionsIntrahepatic Cholangiocarcinoma, Cholangiocarcinoma, IntrahepaticArmsLiver Transplant
3 · Its place in the literature

Who cites it

158 citing papers in PubMed, 2 syntheses or guidelines pooled it, 356 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Present and future of liver transplantation for cholangiocellular carcinoma: moving toward personalized multiparametric transplantability patterns.Transplant international : official journal of the European Society for Organ Transplantation · 2026
    Review
  18. Review
  19. Article
  20. Cholangiocarcinoma 2026: status quo, unmet needs and priorities.Nature reviews. Gastroenterology & hepatology · 2026
    Review

98 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

37 authors at 19 institutions in 7 countries.

G SapisochinMulti-Organ Transplant, Division of General Surgery, Toronto General Hospital, University of Toronto, Toronto, Canada. gonzalo.sapisochin@uhn.ca.
M FacciutoRecanati-Miller Transplantation Institute, The Mount Sinai Medical Center, New York, NY.
L Rubbia-BrandtService de Pathologie Clinique, Faculté de Médecine, Geneva University Hospitals, Geneva, Switzerland.
J MartiRecanati-Miller Transplantation Institute, The Mount Sinai Medical Center, New York, NY.
N MehtaDivision of Gastroenterology, Department of Medicine, University of California, San Francisco, CA.
F Y YaoDivision of Gastroenterology, Department of Medicine, University of California, San Francisco, CA.
E VibertCentre Hépato-Biliaire, Paul Brousse Hospital, AP-HP, Villejuif, France.
D CherquiCentre Hépato-Biliaire, Paul Brousse Hospital, AP-HP, Villejuif, France.
D R GrantMulti-Organ Transplant, Division of General Surgery, Toronto General Hospital, University of Toronto, Toronto, Canada.
R Hernandez-AlejandroDivision of Transplantation, Western University, London, Canada.
C H DaleDivision of Transplantation, Western University, London, Canada.
A CucchettiDepartment of Medical and Surgical Sciences, General and Transplant Surgery Unit, S. Orsola-Malpighi Hospital, Alma Mater Studiorum, University of Bologna, Bologna, Italy.
A PinnaDepartment of Medical and Surgical Sciences, General and Transplant Surgery Unit, S. Orsola-Malpighi Hospital, Alma Mater Studiorum, University of Bologna, Bologna, Italy.
S HwangHepatobiliary Surgery and Liver Transplantation, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
S G LeeHepatobiliary Surgery and Liver Transplantation, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
V G AgopianDumont-UCLA Liver Cancer and Transplant Centers, Pfleger Liver Institute, Department of Surgery, David Geffen School of Medicine at University of California, Los Angeles, CA.
R W BusuttilDumont-UCLA Liver Cancer and Transplant Centers, Pfleger Liver Institute, Department of Surgery, David Geffen School of Medicine at University of California, Los Angeles, CA.
S RizviDivision of Transplant Surgery, William J. von Liebig Transplant Center, Mayo Clinic, Rochester, MN.
J K HeimbachDivision of Transplant Surgery, William J. von Liebig Transplant Center, Mayo Clinic, Rochester, MN.
M MontenovoDepartment of Surgery, Division of Transplantation, University of Washington, Seattle, WA.
J ReyesDepartment of Surgery, Division of Transplantation, University of Washington, Seattle, WA.
M CesarettiDepartment of HPB Surgery and Liver Transplant, Beaujon Hospital, Paris Diderot University-Paris 7, Paris, France.
O SoubraneDepartment of HPB Surgery and Liver Transplant, Beaujon Hospital, Paris Diderot University-Paris 7, Paris, France.
T ReichmanMulti-Organ Transplant Institute, Ochsner Medical Center, New Orleans, LA.
J SealMulti-Organ Transplant Institute, Ochsner Medical Center, New Orleans, LA.
P T W KimAnnette C. and Harold C. Simmons Transplant Institute, Baylor University Medical Center, Dallas, TX.
G KlintmalmAnnette C. and Harold C. Simmons Transplant Institute, Baylor University Medical Center, Dallas, TX.
C SpositoDepartment of Surgery, G.I. Surgery, and Liver Transplantation, Istituto Nazionale Tumori, Milan, Italy.
V MazzaferroDepartment of Surgery, G.I. Surgery, and Liver Transplantation, Istituto Nazionale Tumori, Milan, Italy.
P DutkowskiSwiss HPB and Transplant Center Zurich, Department of Surgery, University Hospital Zurich, Zurich, Switzerland.
P A ClavienSwiss HPB and Transplant Center Zurich, Department of Surgery, University Hospital Zurich, Zurich, Switzerland.
C TosoDivision of Abdominal and Transplantation Surgery, Hepato-pancreato-biliary Centre, Geneva University Hospitals, Geneva, Switzerland.
P MajnoDivision of Abdominal and Transplantation Surgery, Hepato-pancreato-biliary Centre, Geneva University Hospitals, Geneva, Switzerland.
N KnetemanDivision of Transplantation, Department of Surgery, University of Alberta, Edmonton, Alberta, Canada.
C SaundersDivision of Transplantation, Department of Surgery, University of Alberta, Edmonton, Alberta, Canada.
J BruixBarcelona Clínic Liver Cancer Group, Liver Unit, Institut d'Investigacions Biomèdiques, August Pi i Sunyer (IDIBAPS), Hospital Clínic Barcelona, CIBERehd, Barcelona, Spain. jbruix@clinic.ub.es.
iCCA International Consortium
Asan Medical Center · KRBaylor University Medical Center · USDélégation Paris 7 · FRFondazione IRCCS Istituto Nazionale dei Tumori · ITHôpital Paul-Brousse · FRMayo Clinic in Arizona · USMidwestern University · USMount Sinai Hospital · USOchsner Medical Center · USUniversity Hospital of Geneva · CHUniversity of Bologna · ITUniversity of California, Los Angeles · USUniversity of California, San Francisco · USUniversity of Washington · USWestern University · CAConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESToronto General Hospital · CAUlsan College · KRUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelledThe presence of an intrahepatic cholangiocarcinoma (iCCA) in a cirrhotic liver is a contraindication for liver transplantation in most centers worldwide. Recent investigations have shown that "very early" iCCA (single tumors ≤2 cm) may have acceptable results after liver transplantation. This study further evaluates this finding in a larger international multicenter cohort. The study group was composed of those patients who were transplanted for hepatocellular carcinoma or decompensated cirrhosis and found to have an iCCA at explant pathology. Patients were divided into those with "very early" iCCA and those with "advanced" disease (single tumor >2 cm or multifocal disease). Between January 2000 and December 2013, 81 patients were found to have an iCCA at explant; 33 had separate nodules of iCCA and hepatocellular carcinoma, and 48 had only iCCA (study group). Within the study group, 15/48 (31%) constituted the "very early" iCCA group and 33/48 (69%) the "advanced" group. There were no significant differences between groups in preoperative characteristics. At explant, the median size of the largest tumor was larger in the "advanced" group (3.1 [2.5-4.4] versus 1.6 [1.5-1.8]). After a median follow-up of 35 (13.5-76.4) months, the 1-year, 3-year, and 5-year cumulative risks of recurrence were, respectively, 7%, 18%, and 18% in the very early iCCA group versus 30%, 47%, and 61% in the advanced iCCA group, P = 0.01. The 1-year, 3-year, and 5-year actuarial survival rates were, respectively, 93%, 84%, and 65% in the very early iCCA group versus 79%, 50%, and 45% in the advanced iCCA group, P = 0.02.

conclusionPatients with cirrhosis and very early iCCA may become candidates for liver transplantation; a prospective multicenter clinical trial is needed to further confirm these results. (Hepatology 2016;64:1178-1188).

Indexed as

Liver TransplantationAgedBile Duct NeoplasmsCarcinoma, HepatocellularCholangiocarcinomaFemaleHumansLiver NeoplasmsMaleMiddle AgedNeoplasm StagingProspective StudiesRetrospective StudiesSurvival Rate

Identifiers

PMID27481548
OpenAlexW2478338554

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.